News of Note—Inovio-AstraZeneca HPV study, Changsheng and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Investigators have started a phase 2 study at MD Anderson Cancer Center to test MedImmune’s MEDI0457, which AstraZeneca licensed from Inovio, in combination with Imfinzi in HPV-related cancers. Release

> Chinese stock regulators have started delisting Changchun Changsheng Life Sciences from the Shenzhen Stock Exchange over a major vaccine scandal. Xinhua article

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.

> Batavia Biosciences will help the International AIDS Vaccine Initiative to develop a Lassa fever vaccine under a grant from the Coalition for Epidemic Preparedness Innovations. Release